Lesson 9 — World Health Organization Groups II and III Pulmonary Hypertension:
When and How To Treat
By Terence K. Trow, MD, FCCP; Ray Foley, DO, FCCP; and James Klinger, MD,
FCCP
Read/Print This Document
Poststudy Questions
Dr. Trow is Director, Yale University Pulmonary Hypertension Center, and Assistant
Professor, Yale University School of Medicine, New Haven, CT. Dr. Foley is Assistant
Professor of Medicine, University of Connecticut School of Medicine, Division of
Pulmonary/Critical Care Medicine, Farmington, CT. Dr. Klinger is Associate Professor of
Medicine, Brown University, Warren Alpert Medical School, Providence, RI.
Drs. Trow, Foley, and Klinger have disclosed significant relationships with the following
companies/organizations whose products or services may be discussed within this
chapter:
Dr. Trow:
Actelion – grant monies, consultant fee, advisory committee
Gilead Pharmaceuticals – consultant fee, advisory committee
United Therapeutics – consultant fee, advisory committee
Dr. Foley:
Actelion - grant monies, consultant fee, speaker bureau, advisory committee
Gilead Pharmaceuticals – consultant fee, speaker bureau, advisory committee
Pfizer – consultant fee, speaker bureau, advisory committee
United Therapeutics – consultant fee, speaker bureau, advisory committee
Dr. Klinger:
Actelion - grant monies, consultant fee, speaker bureau, advisory committee
Gilead Pharmaceuticals – grant monies, consultant fee, speaker bureau, advisory
committee
Lilly – grant monies
United Therapeutics – consultant fee, speaker bureau, advisory committee
Lesson 10 — An Introduction to Pleural Ultrasonography for the Pulmonary
and Critical Care Physician
By Paul H. Mayo, MD, FCCP; and Peter Doelken, MD, FCCP
Read/Print This Document
Poststudy Questions
Dr. Mayo is Director, MICU, Long Island Jewish Medical Center; and Professor of Clinical Medicine, Albert Einstein College of Medicine, New Hyde Park, NY. Dr. Doelken is Associate Professor, Medical University of South Carolina, Charleston, SC.
Drs. Mayo and Doelken have disclosed no significant relationships with the companies/organizations whose products or services may be discussed within this chapter.
